Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Strata Critical Medical (SRTA) Total Non-Current Liabilities (2020 - 2025)

Strata Critical Medical (SRTA) has disclosed Total Non-Current Liabilities for 6 consecutive years, with $44.9 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities rose 55.1% to $44.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $44.9 million through Dec 2025, up 55.1% year-over-year, with the annual reading at $44.9 million for FY2025, 55.1% up from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $44.9 million at Strata Critical Medical, down from $52.0 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $55.7 million in Q4 2023, with the low at $9.9 million in Q3 2021.
  • Average Total Non-Current Liabilities over 5 years is $37.2 million, with a median of $44.1 million recorded in 2022.
  • The sharpest move saw Total Non-Current Liabilities surged 250.67% in 2022, then crashed 48.04% in 2024.
  • Over 5 years, Total Non-Current Liabilities stood at $13.2 million in 2021, then soared by 229.06% to $43.5 million in 2022, then rose by 28.14% to $55.7 million in 2023, then plummeted by 48.04% to $28.9 million in 2024, then soared by 55.1% to $44.9 million in 2025.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $44.9 million, $52.0 million, and $31.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.